Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® ...

Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow. This results in a ...

OrthoMinds, LLC ("OrthoMinds") is providing notice of a recent data security event. OrthoMinds is notifying clients and potentially impacted individuals of the event. This notice provides information ...

Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...

Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co ...